Use of MAP kinases inhibitors (drugs already approved by the FDA and EMA), for use as treatment in COVID19 patients, preventing the viral spread and inflammatory response resulting from the infection.
In the absence of a vaccine and/or specific treatment, the current therapeutic arsenal offers multiple drugs that can be reused. MAP kinases are involved in the propagation of SARS-CoV2. The aim is to establish the potential of MAPK inhibitors (compounds that block the spread of SARS-CoV-2) as antivirals (as drugs that can be used to treat infections produced by the virus), compared to the most effective therapies currently in use. It would be an immediate option for the treatment of patients with COVID-19.
Principal Investigator: Piero Crespo (IBBTEC)
